Glaxo is acquiring GNLB for $1.30/share, with the deal to close in December, and GNLB is trading for $1.22 as I write this. Considering how small the purchase price ($57M) is compared to what's on GSK's balance sheet, it's hard to imagine how this doesn't go through, and you're getting a respectable 6.56% in 1-2 months.

http://biz.yahoo.com/bw/081029/20081029006599.html

(Disclosure: long GNLB (and wishing I was long yesterday...))